Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[18F]F-ATR
- Development stage
- Preclinical
- Lead developer
- University of Michigan
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
- Administration
- Intravenous
01
Overview
[18F]F-ATR (also referred to as [18F]ATR-F) is a fluorine-18 labeled radiotracer and analog of nevanimibe (ATR-101) developed by the University of Michigan for positron emission tomography (PET) imaging of sterol O-acyltransferase 1 (SOAT1, also known as ACAT1)-mediated cholesterol metabolism. SOAT1 is an endoplasmic reticulum-associated enzyme that catalyzes the esterification of free cholesterol for storage. By targeting SOAT1, [18F]F-ATR is designed to non-invasively image cholesterol utilization and SOAT1 expression in the adrenal glands. This imaging approach aims to identify overproduction of aldosterone from cholesterol in patients with primary aldosteronism (PA), potentially offering a non-invasive alternative to highly invasive adrenal vein sampling (AVS). Additionally, the tracer is being evaluated for imaging cholesterol metabolism in atherosclerosis and cancer.
- Other names
- 18F-labeled nevanimibe analogfluorinated analog of nevanimibefluorine-18 labeled nevanimibe analogfluorine18 labeled nevanimibe analogfluorine 18 labeled nevanimibe analog
02
Targets
ACAT1 (Acyl-coenzyme A:cholesterol O-acyltransferase 1)
Beyond the preview
Go deeper on [18F]F-ATR.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [18F]F-ATR.